EWTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Edgewise Therapeutics Inc (EWTX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the technical indicators show a bullish trend, the lack of significant positive catalysts, weak financial performance, and absence of recent news or influential trading activity suggest that the stock does not currently present an optimal entry point. The investor may consider monitoring the stock for upcoming catalysts, such as the Q2 data on EDG-7500, before making a decision.
The technical indicators for EWTX are moderately bullish. The MACD is positive and expanding, the RSI is neutral at 69.832, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its first resistance level (R1: 33.63) with key support at 31.991.
The MACD and moving averages indicate a bullish trend.
There is no recent news or significant trading activity from insiders, hedge funds, or Congress. Additionally, stock trend analysis predicts potential short-term declines (-6.71% in the next week).
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of $50.2 million, which improved by 26.61% YoY. EPS increased to -0.47, up 11.90% YoY, but the company remains unprofitable.
Analysts are bullish, with JPMorgan and Evercore ISI raising their price targets to $45 and maintaining Overweight/Outperform ratings. JPMorgan added EWTX to its Analyst Focus List as a growth idea, citing upcoming catalysts in 2026.
